Immune peptides: LL-37 and thymosin alpha-1

The immune system is not a single thing. It is a series of layers that respond at different speeds and with different tools. Peptides matter in this system as signals, effectors and building blocks — from antimicrobial peptides on mucosal surfaces to cytokines that direct inflammation.

In this article we focus on LL-37 and thymosin alpha-1, two frequently mentioned compounds that act at different levels of the immune response.

Innate and adaptive immunity

Innate immunity is fast and non-specific. It includes physical barriers, phagocytes, cytokines and antimicrobial peptides. Adaptive immunity is slower but more precise: T and B lymphocytes, antibodies and immunological memory.

Peptides can act at both levels. That is why the same molecule can have an antimicrobial effect in one context and influence inflammatory signals or cell maturation in another.

LL-37: an antimicrobial peptide

LL-37 is a 37-amino-acid peptide formed from the hCAP-18 precursor. It belongs to the cathelicidins and is one of the few human members of that family.

Its structure is amphiphilic — part of the molecule prefers water, part prefers lipids. It can therefore insert into bacterial membranes and damage them. In addition, the following have been described:

• effects on inflammatory cytokines;
• interactions with immune cells;
• involvement in wound healing;
• binding to nucleic acids under certain conditions.

LL-37 is of interest in antibiotic resistance research because it acts differently from classical antibiotics. However, this does not mean it is suitable for treating infections in humans. Peptides can be unstable, cytotoxic at higher concentrations and immunogenic.

Thymosin alpha-1: immunomodulation

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, acetylated at the N-terminus. It derives from thymosin, a peptide complex from the thymus, the organ where T lymphocytes mature.

In research it has been linked to:

• maturation and activation of T cells;
• cytokine modulation;
• use as an adjuvant in vaccine research;
• the immune response in certain viral infections.

In some countries it has been approved for narrow indications, often in a hospital setting. It is not generally approved in the EU. Our product is a research-grade raw material and is not intended for clinical use.

What do the two have in common?

Both peptides:

1. act on the immune system, not directly on a pathogen;
2. have context-dependent effects — the result depends on the environment;
3. are the subject of research, not stand-alone treatment;
4. require precise purity and stability, because impurities can trigger an immune response.

The last point is especially important for immune peptides. In studies that measure inflammatory cytokines, even a small amount of endotoxins or aggregates can distort the results.

Quality and documentation

Our batches are declared with ≥ 98 % purity (HPLC) and identity confirmed by mass spectrometry. For research we recommend:

• checking the batch number on the vial and in the COA;
• storage at −20 °C, protected from light and moisture;
• freshly prepared solutions and adherence to the reconstitution protocol;
• independent analysis of the sample where needed.

For more on what the analytical figures mean, read the article on HPLC and MS. The basic principles are also summarised on the quality and analyses page.

Conclusion

LL-37 and thymosin alpha-1 are biologically important peptides with interesting research paths. Nevertheless, they are not universal immune “boosters” and are not approved for stand-alone treatment. The gap between immunomodulation in the laboratory and clinical benefit is wide — and remains the central question in the research.